Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2110833 | 1.00 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL9122076 | 1.00 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL7818344 | 1.00 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL9123409 | 1.00 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL7818529 | 1.00 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL9123415 | 1.00 | ALOX5 (1.00) | ALOX5HDAC6 | |
| SCHEMBL9030094 | 1.00 | ALOX5 (1.00) | ALOX5HDAC6 | |
| Veliflapon SCHEMBL1004174 | 0.99 | ALOX5 (1.00) | ALOX5HDAC6 | |
| Veliflapon SCHEMBL8798993 | 0.99 | ALOX5 (1.00) | ALOX5HDAC6 | |
| Veliflapon SCHEMBL502932 | 0.99 | ALOX5 (1.00) | ALOX5HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009002746-A1 | DOSING SCHEDULES OF LEUKOTRIENE SYNTHESIS INHIBITORS FOR HUMAN THERAPY | DECODE GENETICS EHF. (IS) | 2008-12-31 | — | — | WO | claimed |
| EP-1871908-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION, STROKE AND PAOD; METHODS OF TREATMENT | Decode Genetics EHF. (IS) | 2008-01-02 | — | — | EP | claimed |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS, INC. (IS) | 2007-12-06 | — | — | US | claimed |
| EP-1718284-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFRACTION, STROKE, AND PAOD; METHODS OF TREATMENT | Decode Genetics EHF. (IS) | 2006-11-08 | — | — | EP | claimed |
| WO-2006105439-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION, STROKE. AND PAOD; METHODS OF TREATMENT | DECODE GENETICS EHF. (IS) | 2006-10-05 | — | — | WO | claimed |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | DECODE GENETICS, INC. (IE) | 2006-01-26 | — | — | US | claimed |
| US-20050282855-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS EHF. (IS) | 2005-12-22 | — | — | US | claimed |
| WO-2005075022-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFRACTION, STROKE, AND PAOD; METHODS OF TREATMENT | DECODE GENETICS EHF. (IS) | 2005-08-18 | — | — | WO | claimed |
| US-20050113408-A1 | peripheral arterial occlusive disease (PAOD); prophylaxis of myocardial infarction by administering an agent that inhibits leukotriene synthesis in vivo for example (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, BAY-X-1005 | DECODE GENETICS EHF. (IS) | 2005-05-26 | — | — | US | claimed |
| US-5358955-A | Antiinflammatory agents | ABBOTT LABORATORIES (US) | 1994-10-25 | — | — | US | claimed |
| US-4970215-A | Substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic acid derivatives and anti-allergic use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-13 | — | — | US | claimed |
| US-8158362-B2 | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype | DECODE GENETICS EHF. (IS) | 2012-04-17 | — | — | US | disclosed |
| US-7851486-B2 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS EHF. (IS) | 2010-12-14 | — | — | US | disclosed |
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | DECODE GENETICS EHF. (IS) | 2010-08-26 | — | — | US | disclosed |
| US-20090030037-A1 | Sustained Release Formulation and Dosing Schedules of Leukotriene Synthesis Inhibitor for Human Therapy | DECODE GENETICS EHF. (IS) | 2009-01-29 | — | — | US | disclosed |
| US-5358955-A | Antiinflammatory agents | ABBOTT LABORATORIES (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994010148-A1 | ARYL AND HETEROARYLMETHOXYPHENYL INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1994-05-11 | — | — | WO | disclosed |
| EP-0344519-B1 | SUBSTITUTED 4-(QUINOLIN-2-YL-METHOXY)PHENYL-ACETIC-ACID DERIVATIVES | BAYER AG (DE) | 1993-04-14 | — | — | EP | disclosed |
| US-5091392-A | Enzyme inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 1992-02-25 | — | — | US | disclosed |
| US-4970215-A | Substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic acid derivatives and anti-allergic use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | ALOX15B, ALOX15, ALOX5 | ALOX5 3/4885HDAC6 4504/4885 |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | ALOX15B, ALOX15, ALOX5 | ALOX5 3/4885HDAC6 4504/4885 |
| US-20050113408-A1 | peripheral arterial occlusive disease (PAOD); prophylaxis of myocardial infarction by administering an agent that inhibits leukotriene synthesis in vivo for example (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, BAY-X-1005 | ALOX5, ALOX15, ALOX12 | ALOX5 1/4885HDAC6 4699/4885 |
| US-20090030037-A1 | Sustained Release Formulation and Dosing Schedules of Leukotriene Synthesis Inhibitor for Human Therapy | LTC4S, LTB4R, LTB4R2 | ALOX5 8/4885HDAC6 2729/4885 |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | PLAAT3, PLAAT2, PLA2G7 | ALOX5 13/4885HDAC6 4187/4885 |
| US-20050282855-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | PLAAT3, PLAAT2, PLA2G7 | ALOX5 49/4885HDAC6 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.